VivoSim reports 13.4M shares outstanding after July warrant exercises
VivoSim (Nasdaq: VIVS) said it regained Nasdaq Rule 5550(b)(1) compliance on Aug. 4, 2026 after meeting the $2.5 million minimum stockholders’ equity requirement. The company reported July cash inflows of $5.0 million milestone plus $1.0 million escrow release tied to an FXR program sale to Eli Lilly, and a July 17 financing raising $4.0 million gross ($3.6 million net). Shares rose from 3.19M (Jun 30) to 13.39M (Aug 3) after 9.90M warrant exercises; cash was about $10.1M as of Aug 3.
How this was made
The 30-second read
Why it matters
Regaining Nasdaq compliance reduces the probability of delisting or forced corrective actions. However, the company’s share count rose sharply due to warrant exercises, which can dilute existing holders even if cash inflows improve liquidity.
Market read
Traders get a two-sided update: listing-risk relief plus a concrete dilution datapoint and cash inflow figures, alongside reiterated FY2027 revenue growth guidance.
What to watch
The release is preliminary and unaudited, and it does not quantify how the $6.0M July cash inflow changes runway versus ongoing burn or future financing needs.
Background
VivoSim previously faced Nasdaq equity compliance issues tied to minimum stockholders’ equity, and it also completed a July financing with pre-funded and common warrants.
Ticker impact
VivoSim says it regained Nasdaq Rule 5550(b)(1) compliance and reports a jump in shares outstanding to 13.39M after July warrant exercises.
Near-term: relief bid on compliance, offset by dilution overhang from ~9.9M warrant-exercise shares.
The article provides two actionable datapoints: Nasdaq compliance regained (risk-off factor removed) and a material increase in shares outstanding tied to warrant exercises (risk-on for dilution).
Market effects
NAM/3D human tissue model peers may face similar equity-compliance and financing dynamics, but this is company-specific.
Limited, US microcap listing-compliance story.
Low; no direct global market linkage beyond biotech financing norms.
Counterpoint
The compliance notice may be largely mechanical, while the dilution from warrant exercises could dominate the stock’s medium-term risk/reward.
Key entities
- companyVivoSim Labs, Inc.
Nasdaq-listed NAM 3D human cellular models provider that regained Nasdaq equity compliance and disclosed July warrant-driven share issuance.
- counterpartyEli Lilly
Counterparty to VivoSim’s prior FXR program sale, tied to a $5.0M milestone payment and $1.0M escrow release in July 2026.
- regulatorNasdaq Listing Qualifications Staff
Notified VivoSim on Aug 4, 2026 that it regained compliance with Nasdaq Listing Rule 5550(b)(1).
